Recombinant anti-RANKL monoclonal antibody(Jiangsu Pacific-Meinuoke)

重组抗RANKL单克隆抗体（江苏太平洋美诺克）

Report date: 2024/10/30 20:00:43

Base Information

Drug NameRecombinant anti-RANKL monoclonal antibody(Jiangsu Pacific-Meinuoke)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of Actionanti-Tumor necrosis factor ligand superfamily member 11
TargetsTumor necrosis factor ligand superfamily member 11
Therapy Area/IndicationsOsteoporosis, Postmenopausal
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesJiangsu Pacific Minok Biopharmaceutical Co., Ltd.
China Registration ClassN/A

Develop Information

Active CompaniesJiangsu Pacific Minok Biopharmaceutical Co., Ltd.
Inactive CompaniesN/A
Active IndicationsOsteoporosis, Postmenopausal
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A